Loading…
Data as of .
| Market | Companies | Market cap | 6M (cap-wt) | Median revenue growth |
|---|---|---|---|---|
| United States | 454 | $8.33T | +28.2% | +11% |
| Switzerland | 29 | $944B | +18.9% | +1% |
| China | 425 | $855B | -3.4% | +2% |
| Japan | 69 | $474B | +9.4% | +8% |
| United Kingdom | 13 | $446B | -1.0% | +3% |
| Hong Kong | 108 | $423B | +5.7% | +16% |
| India | 105 | $402B | +16.7% | +21% |
| France | 18 | $277B | +9.5% | +2% |
| Germany | 18 | $271B | +27.9% | +2% |
| Denmark | 11 | $263B | +14.3% | +6% |
| South Korea | 55 | $159B | -13.5% | +12% |
| Australia | 19 | $135B | +60.4% | +4% |
| Sweden | 21 | $56.4B | +16.9% | +3% |
| Taiwan | 37 | $40.6B | +64.9% | +7% |
| Netherlands | 3 | $32.1B | +17.6% | +2% |
| Canada | 10 | $25.1B | +28.5% | +15% |
| Italy | 8 | $24.7B | +9.1% | +3% |
| Spain | 6 | $17.6B | +6.8% | +19% |
| Finland | 3 | $16.9B | +35.6% | +34% |
| Singapore | 5 | $4.94B | -16.8% | -3% |
| Poland | 4 | $3.13B | +5.2% | +17% |
| Norway | 1 | $599M | +32.4% | +19% |
| Company | Market | Industry | Market cap | 1M | 6M | Revenue growth | Op. margin | Fwd P/E |
|---|---|---|---|---|---|---|---|---|
| Lilly (Eli) LLY | United States | Pharmaceuticals: Major | $1.30T | +8% | +36% | +46% | 51% | 29.5× |
| Johnson & Johnson JNJ | United States | Pharmaceuticals: Major | $656B | +5% | +20% | +8% | 26% | 24.2× |
| AbbVie ABBV | United States | Pharmaceuticals: Major | $506B | -1% | +35% | +11% | 36% | 18.1× |
| Roche RO.SW | Switzerland | Pharmaceuticals: Major | $381B | +3% | +21% | -1% | 31% | 19.9× |
| Merck & MRK | United States | Pharmaceuticals: Major | $340B | -7% | +23% | +5% | 18% | 16.4× |
| UnitedHealth UNH | United States | Managed Health Care | $314B | -17% | -8% | +3% | 5% | 15.4× |
| Novartis NOVN.SW | Switzerland | Pharmaceuticals: Major | $285B | +4% | +11% | -4% | 30% | 17.5× |
| AstraZeneca AZN.L | United Kingdom | Pharmaceuticals: Major | $278B | +8% | -2% | +5% | 23% | 17.6× |
| Thermo Fisher Scientific TMO | United States | Medical Specialties | $257B | +1% | +53% | +8% | 19% | 25.7× |
| Amgen AMGN | United States | Biotechnology | $240B | +1% | +34% | +9% | 36% | 18.3× |
| Gilead Sciences GILD | United States | Biotechnology | $210B | +8% | +30% | +7% | 38% | 19.9× |
| Abbott Laboratories ABT | United States | Medical Specialties | $181B | +2% | +18% | +10% | 14% | 17.9× |
| Novo Nordisk A/S NOVO-B.CO | Denmark | Pharmaceuticals: Major | $177B | +4% | -6% | +6% | 48% | 11.8× |
| Danaher DHR | United States | Medical Specialties | $161B | +2% | +34% | +6% | 21% | 25.1× |
| Pfizer PFE | United States | Pharmaceuticals: Major | $160B | -7% | +9% | +1% | 26% | 9.9× |
| Intuitive Surgical ISRG | United States | Medical Specialties | $146B | -4% | -6% | +20% | 32% | 34.8× |
| Vertex Pharmaceuticals VRTX | United States | Pharmaceuticals: Major | $136B | +4% | +25% | +11% | 35% | 28.5× |
| Medtronic MDT | United States | Medical Specialties | $129B | +6% | +30% | +10% | 20% | 16.8× |
| McKesson MCK | United States | Medical Distributors | $125B | +5% | +44% | +8% | 2% | 22.1× |
| Bristol Myers Squibb BMY | United States | Pharmaceuticals: Major | $122B | -3% | +3% | +4% | 33% | 9.2× |
| Stryker SYK | United States | Medical Specialties | $121B | +5% | -1% | +8% | 25% | 19.9× |
| Sanofi SAN.PA | France | Pharmaceuticals: Major | $114B | +17% | +13% | +15% | 27% | 9.7× |
| CVS Health CVS | United States | Drugstore Chains | $104B | -14% | -13% | +7% | 4% | 9.6× |
| HCA Healthcare HCA | United States | Hospital/Nursing Management | $99.5B | +2% | +20% | +6% | 15% | 15.6× |
| GSK GSK.L | United Kingdom | Pharmaceuticals: Major | $97.9B | -1% | -3% | +4% | 25% | 10.4× |
| Regeneron Pharmaceuticals REGN | United States | Pharmaceuticals: Major | $97.8B | +17% | +46% | +19% | 30% | 11.8× |
| EssilorLuxottica EL.PA | France | Medical Specialties | $91.9B | +20% | +5% | +8% | 12% | 24.8× |
| Elevance Health ELV | United States | Managed Health Care | $86.6B | -9% | +2% | +4% | 4% | 13.9× |
| Moderna MRNA | United States | Biotechnology | $79.6B | -19% | +309% | +13% | -116% | n/a |
| Cigna CI | United States | Managed Health Care | $75.2B | -7% | +1% | +7% | 4% | 8.8× |
| Chugai Pharmaceutical 4519.T | Japan | Pharmaceuticals: Major | $75.2B | +14% | -8% | +17% | 50% | 23.7× |
| Merck KGaA MRK.DE | Germany | Pharmaceuticals: Major | $71.3B | +2% | +16% | +1% | 19% | 17.4× |
| Takeda Pharmaceutical 4502.T | Japan | Pharmaceuticals: Major | $69.8B | +10% | +30% | +6% | 18% | 51.0× |
| Cencora COR | United States | Medical Distributors | $66.5B | +1% | +32% | +5% | 1% | 17.7× |
| Cardinal Health CAH | United States | Medical Distributors | $64.3B | +8% | +40% | +10% | 1% | 21.1× |
| WuXi AppTec 603259.SS | China | Pharmaceuticals: Major | $64.2B | -2% | +40% | +32% | 43% | 17.0× |
| Wuxi Apptec 2359.HK | Hong Kong | Pharmaceuticals: Major | $64.1B | -3% | +51% | +38% | 44% | 19.5× |
| CSL CSL.AX | Australia | Biotechnology | $63.7B | +2% | +102% | -2% | 26% | 21.5× |
| Boston Scientific BSX | United States | Medical Specialties | $63.3B | -4% | -23% | +9% | 21% | 14.1× |
| Edwards Lifesciences EW | United States | Medical Specialties | $60.5B | +19% | +27% | +13% | 29% | 32.3× |
| Bayer BAYN.DE | Germany | Pharmaceuticals: Major | $60.3B | +29% | +48% | 0% | 13% | 12.3× |
| argenx SE Sponsored ADR ARGX | United States | Biotechnology | $59.1B | +8% | +17% | +71% | 29% | 29.0× |
| Becton Dickinson BDX | United States | Medical Specialties | $58.9B | +12% | +48% | -7% | 16% | 16.3× |
| Idexx Laboratories IDXX | United States | Medical Specialties | $55.0B | +25% | +26% | +12% | 32% | 42.9× |
| Lonza LONN.SW | Switzerland | Biotechnology | $53.9B | +7% | +36% | -11% | 25% | 36.1× |
| Siemens Healthineers SHL.DE | Germany | Medical Specialties | $53.7B | +6% | +27% | +1% | 14% | 18.9× |
| Galderma GALD.SW | Switzerland | Pharmaceuticals: Major | $51.9B | +7% | +18% | +16% | 19% | 45.7× |
| Medline MDLN | United States | Medical Specialties | $51.5B | +10% | +8% | +12% | 6% | 25.6× |
| Agilent Technologies A | United States | Medical Specialties | $50.0B | +2% | +56% | +9% | 24% | 27.0× |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | United States | Pharmaceuticals: Generic | $49.3B | +3% | +23% | -4% | 19% | 15.0× |